Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Desmoteplase in Acute Ischemic Stroke (DIAS-2)
NCT00111852Phase 3Completed
- Sponsor
- Forest Laboratories
- Start
- Apr 2005
- Primary completion
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of desmoteplase in ischemic stroke (3 arms), sponsored by Forest Laboratories. Primary endpoints: National Institutes of Health Stroke Scale at Day 90, Modified Rankin Scale at Day 90 and 1 more. Started Apr 2005; status: completed.
02
Drugs
desmoteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00111852.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00111852.